2022
Intratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and Letters
2017
Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Research 2017, 77: 566-578. PMID: 27872098, PMCID: PMC5582957, DOI: 10.1158/0008-5472.can-16-1901.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerTNBC cell linesPairwise drug combinationsClinical translationAggressive diseaseCombination therapyBreast cancerPreclinical proofDrug combinationsCombination treatmentInvestigational drugsSingle agentSensitivity patternCell sensitivityCell linesTherapyApoptotic activityAnticancer activityDownregulated genesMitogenic signalingCrizotinibBlockadeClinicAgentsCancer
2015
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European Journal Of Cancer Prevention 2015, 25: 3-8. PMID: 25642790, PMCID: PMC4885537, DOI: 10.1097/cej.0000000000000124.Peer-Reviewed Original ResearchConceptsCancer prevention clinicSelective estrogen receptor modulatorsPostmenopausal womenEstrogen receptor modulatorsChemoprevention uptakePrevention clinicReceptor modulatorsBreast cancer chemopreventionRetrospective chart reviewSerious side effectsChemoprevention medicationsChemopreventive optionChart reviewMean ageAromatase inhibitorsBreast cancerBone densityStudy populationCancer chemopreventionGeneral populationExemestaneSide effectsChemopreventionClinicWomen